Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenovirus-specific cytotoxic T-lymphocytes (New York Medical College)
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Adenovirus-specific cytotoxic T-lymphocytes (ADV-CTLs) is an investigational adoptive cell therapy developed by New York Medical College for the treatment of refractory adenovirus infections in immunocompromised patients. The therapy consists of T-lymphocytes derived from HLA-matched or mismatched related donors that are specifically sensitized against adenovirus antigens. The manufacturing process utilizes the Miltenyi CliniMACS Prodigy Cytokine Capture System, where donor cells are stimulated with the MACS GMP PepTivator AdV5 Hexon to isolate and expand virus-specific T cells. By intravenously administering these targeted CTLs, the therapy aims to restore cellular immunity against adenovirus, specifically targeting and eliminating virus-infected cells. It is primarily being evaluated in pediatric and young adult populations following allogeneic hematopoietic stem cell transplantation (AlloHSCT), solid organ transplantation, or in those with primary immunodeficiencies.
- Other names
- Related donor ADV-CTLsAdenovirus-specific CTLsADV-specific CTLs
02
Targets
HAdV-hexon-pMHC (Adenovirus hexon protein-derived peptide–Major Histocompatibility Complex)
Beyond the preview
Go deeper on Adenovirus-specific cytotoxic T-lymphocytes (New York Medical College).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenovirus-specific cytotoxic T-lymphocytes (New York Medical College).